AbbVie Dermatology: Let’s change lives

AbbVie is committed to the pursuit of innovation to give dermatology patients the opportunity to feel free in their own skin.

A Legacy of Innovation

A deep understanding of dermatology and immune-mediated disease has long been at the core of AbbVie innovation. After more than a decade of research, we’ve developed unique technologies to optimize therapeutics in the area of dermatology, and we’re focused on delivering treatments in areas of high unmet medical need and where current treatment options do not meet patient expectations.

Learn more about our Dermatology priorities »


This chronic disease of the immune system triggers skin inflammation and causes skin cells to be produced faster than normal, forming the thick, red, itchy, flaky patches known as plaques.

Atopic Dermatitis (AD)

A chronic inflammatory skin disease that is characterized by skin erosion, oozing and crusting, redness, intense itching and dry skin.

Hidradentis Suppurativa (HS)

A chronic, inflammatory disease that can be distinguished by lesions, nodules and abscesses on the skin, particularly where oil and sweat glands are located or where skin rubs together.

Psoriatic Arthritis

A type of inflammatory arthritis that triggers joint pain, stiffness and swelling. About 30 percent of people with psoriasis also develop psoriatic arthritis.

Leading the Way

The Road Ahead

Commitment to Patients

We have a bold vision for the future: one where we have an answer for even more patients. Years of clinical studies have revealed a greater need for medical solutions to accommodate a diverse community of patients.

The Road Ahead

The Road Ahead

Guided by real patient journeys, we’re investigating several immune-mediated skin diseases and continuing our commitment with long-term investments in research and development, delivering innovation in patient support, and providing high-quality education for patients and physicians.

New Pathways

New Pathways

Our pipeline currently features two late-stage investigational compounds for dermatology patients. One is a biologic that selectively blocks IL-23, a key protein linked to psoriasis and psoriatic arthritis. The other, an oral JAK1-selective inhibitor, is being explored as a new treatment for patients with AD and psoriatic arthritis.

Our Pathways

TNF- α

A cytokine that contributes to the induction and maintenance of the inflammatory immune response.


An enzyme partially responsible for signaling part of the immune system and is responsible for activation of immune cells involved in autoimmune disorders.


A key protein involved in skin inflammation which has been linked to an overactive immune system.


A protein that regulates the production of other key pro-inflammatory proteins.

Committed to Dermatology

In the News

AbbVie Reinforces Leadership in Dermatology With New Data Showcasing Research Advancements Across Growing Portfolio at the 27th European Academy of Dermatology and Venereology (EADV) Congress
Read More

AbbVie Presents New Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting
Read More

AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
Read More

AbbVie Showcases New, Late-Breaking Investigational Data at 2018 American Academy of Dermatology (AAD) Annual Meeting
Read More

Join Our Team

Our team of immunology experts is focused on improving the standard of care for this generation and the next. We’re committed, curious, and passionate; and we’re hiring.

Seeing Clear: What the Future Holds for Psoriasis

How unraveling more mysteries of the immune system may help guide better health outcomes for patients.

Get the Latest from AbbVie

Stay up to date on recent news, articles, and more by subscribing to e-mail alerts for one or more of our news topics.

This site uses cookies to personalize content, save your preferences and track the site’s performance. Learn more, including how to disable certain cookies on our Privacy Page. Click OK to continue.